(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.31%) $78.35
(0.33%) $2.15
(0.41%) $2 318.10
(1.78%) $27.17
(-0.39%) $961.55
(0.03%) $0.929
(-0.02%) $10.87
(0.00%) $0.797
(0.00%) $91.45
Live Chart Being Loaded With Signals
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...
Stats | |
---|---|
Today's Volume | 46 741.00 |
Average Volume | 95 534.00 |
Market Cap | 9.00M |
EPS | $0 ( 2024-03-29 ) |
Next earnings date | ( $-0.790 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.390 |
ATR14 | $0.0200 (1.44%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Werner Milton H. | Buy | 45 000 | Stock Option (right to buy) |
2024-04-01 | Lees-rolfe Garth | Buy | 90 000 | Stock Option (right to buy) |
2024-04-01 | Lees-rolfe Garth | Sell | 5 834 | Stock Option (right to buy) |
2023-06-30 | Berman Dennis N | Buy | 6 667 | Stock Option (right to buy) |
2023-06-30 | Dion Gisele | Buy | 6 667 | Stock Option (right to buy) |
INSIDER POWER |
---|
96.47 |
Last 62 transactions |
Buy: 1 923 769 | Sell: 2 120 717 |
Volume Correlation
Inhibikase Therapeutics, Correlation
10 Most Positive Correlations | |
---|---|
ECOR | 0.835 |
CPLP | 0.833 |
PROV | 0.828 |
SVOK | 0.82 |
CLST | 0.816 |
BHFAO | 0.815 |
CFBK | 0.815 |
MREO | 0.811 |
OCCIO | 0.809 |
HMST | 0.806 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Inhibikase Therapeutics, Correlation - Currency/Commodity
Inhibikase Therapeutics, Financials
Annual | 2023 |
Revenue: | $260 500 |
Gross Profit: | $83 102.00 (31.90 %) |
EPS: | $-3.57 |
FY | 2023 |
Revenue: | $260 500 |
Gross Profit: | $83 102.00 (31.90 %) |
EPS: | $-3.57 |
FY | 2022 |
Revenue: | $123 440 |
Gross Profit: | $116 717 (94.55 %) |
EPS: | $-4.26 |
FY | 2021 |
Revenue: | $3.10M |
Gross Profit: | $3.10M (100.00 %) |
EPS: | $-0.810 |
Financial Reports:
No articles found.
Inhibikase Therapeutics,
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators